For immediate release

11 April 2024

==> picture [596 x 198] intentionally omitted <==

CSL Australia Investor Site Tour Presentations

The presentation materials to be used for an Investor Site Tour being conducted by CSL (ASX:CSL; USOTC:CSLLY) in Melbourne today are attached for the information of investors.

Authorised By

Fiona Mead

Company Secretary

For further information, please contact:

Investors: Bernard Ronchi Director, Investor Relations CSL Limited P: +61 3 9389 3470 E: [email protected]

Stephen McKeon Director, Investor Relations CSL Limited P: 61 402 231 696 E: [email protected]

Media:

Bernadette Murdoch Communications CSL Limited P: +61 449 950 7451 E: [email protected]

Investor Tour CSL Behring & CSL Seqirus April 2024

IMPORTANT NOTICE AND DISCLAIMER

This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, CSL ) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with CSL's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange ( ASX ), available at www.asx.com.au This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire CSL shares or other securities.

Legal Notice

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of CSL or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of CSL or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to CSL, including statements regarding CSL's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to CSL's business and operations, market conditions, results of operations and financial conditions, products in research, risk management practices, climate change and other environmental and energy transition scenarios. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", “project,” "intend", "outlook", "target", "assume" and "guidance" and other similar expressions.

The forward-looking statements are based on CSL's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect CSL's business and operations in the future. CSL does not give any assurance that the assumptions will prove to be correct. The forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors, many of which are beyond the control of CSL, that could cause the actual results, performances or achievements of CSL to be materially different to future results, performances or achievements expressed or implied by the statements . Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, advances in environmental protection processes, uncertainty and disruption caused by the COVID-19 pandemic and CSL’s ability to protect its patents and other intellectual property.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as at the date of the presentation. Except as required by applicable laws or regulations, CSL does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

TRADEMARKS

Except where otherwise noted, brand names designated by a ™ or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.

==> picture [109 x 10] intentionally omitted <==

==> picture [519 x 419] intentionally omitted <==

Acknowledgement of Country

CSL acknowledges Traditional Owners of Country throughout Australia and recognises their continuing connection to lands, waters and communities. We pay our respects to all Aboriginal and Torres Strait Islander cultures; and to Elders past and present.

Artwork by Simone Thomson as featured in CSL’s Reflect Reconciliation Action Plan

==> picture [109 x 10] intentionally omitted <==

==> picture [122 x 108] intentionally omitted <==

CSL Behring Broadmeadows Investor Tour

Mike Deem

Andrew Hodder

Manufacturing & Site Head CSL Behring Australia

Head Of Operations CSL Behring

April 2024

Visitor Safety Procedures

While you are in the facility you will be escorted by CSL Behring personnel

In the event of an emergency follow the instructions provided by your guide

Alert Tone – “BEEP-BEEP-BEEP”

Standby and await instructions of wardens
Evacuate Tone – “WHOOP-WHOOPWHOOP”
Evacuate as instructed by your wardens

==> picture [519 x 420] intentionally omitted <==

==> picture [109 x 10] intentionally omitted <==

Site Safety Rules

==> picture [160 x 166] intentionally omitted <==

==> picture [109 x 10] intentionally omitted <==

Who we are

CSL is a global biotechnology leader that develops and delivers innovative medicines that save lives, protects public health and helps people with life-threatening medical conditions live full lives.

Cheryl Blackwell Johnson Living with HAE

==> picture [104 x 10] intentionally omitted <==

==> picture [95 x 72] intentionally omitted <==

Leading global biotech company

We are a global biotechnology leader that develops and delivers innovative medicines that save lives, protects public health and helps people with life-threatening medical conditions live full lives

==> picture [31 x 31] intentionally omitted <==

[Countries of operations ] 40[+] around the world

R&D Manufacturing Commercial Operations Testing Laboratory Distribution Warehousing Administration Regional Sales AND/OR Distribution

in annual US$ 9 Manufacturing sites across 6 countries 13.3bn revenue (FY23) Australia China Germany Switzerland UK

==> picture [29 x 30] intentionally omitted <==

Employees around the world[1]

==> picture [53 x 32] intentionally omitted <==

32,000[+]

R&D

==> picture [45 x 44] intentionally omitted <==

investment in the last 5 financial years

US$5.1bn

==> picture [53 x 31] intentionally omitted <==

2,000[+]

R&D employees[1]

340+

Plasma collection centres primarily in the US[1]

==> picture [109 x 10] intentionally omitted <==

1. As at 31 December 2023.

CSL group operating structure

==> picture [99 x 30] intentionally omitted <==

Global Biotherapeutics Leader

==> picture [92 x 21] intentionally omitted <==

Global Influenza Vaccines Leader

==> picture [77 x 30] intentionally omitted <==

Global Specialty Pharma Leader

		Global Biotherapeutics Leader		Global Influenza Vaccines Leader		Global Specialty Pharma Leader
	•	One of the world’s largest collectors	•	One of the largest influenza vaccine	•	Global specialty pharmaceuticals
		of plasma and providers of plasma		companies in the world by revenue		business that is a leader in iron
	•	therapies Develops and delivers high-quality	•	Formed in 2015 through the combination of bioCSL and Novartis		therapies, dialysis, nephrology and rare diseases
		medicines that treat rare and serious		influenza vaccines business	•	Specialises in strategic global
Overview	• • •	diseases Manufactures, markets and develops plasma and recombinant therapies Early-stage research on plasma and non-plasma therapies (excluding influenza) Receives license and royalty income from commercialisation of IP	• •	In Australia and New Zealand, a leading provider of in-licensed vaccines and specialty pharmaceuticals Supplier to the Australian Government for a range of products, including antivenoms and Q fever vaccine	•	partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare Joint company, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) with Fresenius Medical Care, a global leader in dialysis
	•	Focuses on five key therapeutic
		areas1
% of Revenue2		70%		15%		15%
	•	Operations in over 40 countries	•	Operations in over 15 countries	•	Markets in over 100 countries
Global Footprint	• •	Markets in over 100 countries 6 manufacturing sites in 5 countries	• •	3 manufacturing sites in 3 countries Research & production facilities and manufacturing plants across North	• •	Broad global network of affiliates and partners Certain final stage production
				America, Europe and Australia		processes are outsourced to contract
						manufacturing organisations

Source: Company filings.

9 1. Five key therapeutic areas are immunology, hematology, respiratory, cardiovascular & metabolic and transplant. 2. Based on FY23 revenue.

==> picture [109 x 10] intentionally omitted <==

CSL Behring: Driving sustainable, profitable growth

Working together from Donor to Patient

==> picture [884 x 324] intentionally omitted <==

----- Start of picture text -----

PLASMA COLLECTION MANUFACTURING COMMERCIALISATION
2
1 3
Deploy Rika , Deliver Horizon 1 yield Outpace market
Nomogram A/I , improvements ; advance growth in Ig ,
digital transformation Horizon 2 and focus on Haemophilia B and
and operational OPEX reduction through HAE
excellence Operational Excellence
----- End of picture text -----

==> picture [109 x 10] intentionally omitted <==

CSL Behring – Global manufacturing presence

==> picture [147 x 78] intentionally omitted <==

==> picture [148 x 78] intentionally omitted <==

==> picture [147 x 78] intentionally omitted <==

==> picture [148 x 78] intentionally omitted <==

Bern, Switzerland

Broadmeadows, Australia

Marburg, Germany

Kankakee, Illinois, US

Wuhan, China

Core products: • Core products: immunoglobulins & immunoglobulins & albumin albumin
Specialty products: coagulation factors, critical care
Specialty products: anti-D-hyperimmune
Core products: human albumin, coagulation factors, critical care
Specialty products: hyperimmunes
Core products: • Core products: albumin, albumin, fractionation for immunoglobulins intermediate pastes
Specialty products: alpha1-proteinase inhibitor

• Toll plasma services for Australia, New Zealand, Hong Kong, Malaysia & Taiwan

==> picture [109 x 10] intentionally omitted <==

CapEx investments are providing capacity for growth

CSL expects CapEx investment needs to reduce as major projects are now coming online

==> picture [918 x 364] intentionally omitted <==

----- Start of picture text -----

Annual CapEx Spend
New Capacity Online
30%
CSL Plasma Centers at Start of FY
Reduction in
IG Production CapEx Spend
COVID Dip
330
303
277
237
206
180
Marburg / Marburg
148 External Filling Fractionation
127
Broadmeadows Kankakee Bern Broadmeadows Broadmeadows
IG Bulk Fractionation Ig Bulk Albumin Bulk Fractionation
FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24
----- End of picture text -----

==> picture [109 x 10] intentionally omitted <==

From donor to patient: Manufacturing plasma biotherapies

The process starts with plasma donors who play a vital role

Frozen plasma and plasma pastes are transported to site

Plasma and pastes are held in cold storage until needed

Separation of Reconstitution and whole plasma into filtration to manufacture component parts biotherapies

==> picture [84 x 84] intentionally omitted <==

FILLING

Formulation and filling of bulk product into vials

VISUAL INSPECTION Safety and quality checks of every vial

QUALITY CONTROL / TESTING

Testing of finished products and all manufacturing consumables

PACKING

Labelling, boxing and packing all products ready for distribution to patients

HOSPITALS & PATIENTS

Finished products are distributed to hospitals and direct to patients around the world

==> picture [109 x 10] intentionally omitted <==

WELCOME TO BROADMEADOWS

==> picture [109 x 10] intentionally omitted <==

CSL BEHRING BROADMEADOWS

Site opened 1994 Commercial facilities for 1,200+ employees production of PRIVIGEN®, Domestic AlbuRx® and plasma Hizentra® fractionation for Australia, New Recombinant Zealand, Hong manufacturing Kong, Taiwan, facility for clinical Malaysia trial production

Recombinant manufacturing facility for clinical trial production

==> picture [109 x 10] intentionally omitted <==

==> picture [57 x 51] intentionally omitted <==

==> picture [423 x 85] intentionally omitted <==

OUR WORKFORCE

==> picture [141 x 140] intentionally omitted <==

1,268 92% 89% EMPLOYEES FULL TIME HOURS PERMANENT EMPLOYEES 40 years 1 in 5 38% AVERAGE AGE EMPLOYEES ARE PEOPLE EMPLOYEES ARE FEMALE MANAGERS 10,368 years 1 in 10 29.5% OF COMBINED SERVICE EMPLOYEES ARE OVER 55 OF PEOPLE MANAGERS YEARS OLD ARE FEMALE 81% 8 years 90% EMPLOYEE ENGAGEMENT AVERAGE TENURE OF EMPLOYEES IN STEM INDEX SCORE

==> picture [109 x 10] intentionally omitted <==

Our Customers

GLOBAL COMMERCIAL SUPPLY

==> picture [125 x 27] intentionally omitted <==

Plasma supplied through CSL Plasma sourced in the USA

REGIONAL DOMESTIC SUPPLY

Contract Domestic Manufacturing supply agreements:

National Blood Authority (Australia)
NZ Blood (New Zealand)

==> picture [121 x 26] intentionally omitted <==

Future expansion will support Filling and Packing operations for CSL Seqirus Tullamarine site

Taiwan Blood Services Foundation (Taiwan)
Pusat Darah Negara (Malaysia)
Hong Kong Red Cross Blood Transfusion Service

==> picture [109 x 10] intentionally omitted <==

CSL BEHRING BROADMEADOWS

Haemophilia and Specialty Products Facility (Domestic/Contract)
Turner Facility (PRIVIGEN®, Hizentra®)
Facility A (AlbuRx®, Alburex®)
Facility F (Base Fractionation)
Biotech Manufacturing Facility (Recombinant)

==> picture [846 x 337] intentionally omitted <==

----- Start of picture text -----

4
3
2
5
1
----- End of picture text -----

==> picture [109 x 10] intentionally omitted <==

Product Portfolio

CSL Behring Broadmeadows

Critical Care

Albumin solutions Human Albumin Behring[®] Alburex[®] , AlbuRx[®] , Albumex[®, ] Albuminar[®]

Inhibitors

Berinert[®] P, Haegarda[®, ] Berinert SC[®] Kybernin[®] P

Other trauma therapies Beriplex[®] P/N, Coaplex, Kcentra[®] RiaSTAP[®] Haemocomplettan[®] P Thrombotrol[®] Prothrombinex[®]

Wound Healing

Beriplast® P Combi-Set Fibrogammin®, Corifact®, Cluvot® Fibrinogen active substance

Pulmonology

Zemaira[®] Respreeza[®]

Immunology

Polyvalent immunoglobulins Privigen[®] , Privigen® AU Hizentra[®] Carimune® NF Sandoglobulin® Intragam® Evogam ® Hyperimmunes Rhophylac® , Rhesogam CytoGam® Beriglobin® P Berirab® P Hepatitis B IG P Behring® Tetagam® P

Domestic Hyperimmunes produced at Broadmeadows

Cytomegolavirus Immunoglobulin ~~-~~ VF Hepatitis B Immunoglobulin ~~-~~ VF ~~-~~ Rh(D) Immunoglobulin (Anti D) Tetanus Immunoglobulin ~~-~~ VF IM Tetanus Immunoglobulin ~~-~~ VF IV Zoster Immunoglobulin ~~-~~ VF Normal Immunoglobulin ~~-~~ VF

KEY Current portfolio Future filling capacity

Coagulation

Plasma-derived factor II Human Thrombin active substance Recombinant factor VIII Afstyla[®]

Recombinant factor IX Idelvion[®]

Factor VIII:C/von Willebrand factor Haemate[® ] P, Humate[® ] P, Voncento[®] , Biostate[®]

Plasma-derived factor VIII Beriate[® ] P, Biostate[®] Plasma-derived factors X Factor X P Behring[®] Gene therapy - Hemgenix®

CSL Seqirus

Afluria[®]

Flucelvax[®] Tetra PNS (Antivenoms)

==> picture [109 x 10] intentionally omitted <==

MORE THAN A DECADE OF SUSTAINED GROWTH AND ALMOST A$2B IN CAPITAL INVESTMENT

2013 2014 2017 2022 Turner Biotechnology Facility A PRIVIGEN Manufacturing AlbuRx Facility Facility

FUTURE

Filling capacity expansion Ig yield Albumin Facility F Base capacity Fractionation expansion and Logistics Hub

==> picture [109 x 10] intentionally omitted <==

Sustainability Initiatives at Broadmeadows

CSL target: 40% reduction of Scope 1&2 emissions by 2030 against a baseline of average emissions across FY19-21

Power Purchase Agreement for Australian renewable electricity will make a substantial contribution to achieving target
Broadmeadows is the largest proportion of CSL’s electricity use and emissions in Australia
Agreement starts in January 2025
Energy efficiency projects focused on steam generated from natural gas to reduce Scope 1 emissions are being investigated

==> picture [421 x 301] intentionally omitted <==

Local sustainability initiatives

On site ethanol recovery and recycling for reuse in manufacturing processes
Evaluating waste reduction involving site audits and a workshop with waste service providers to set priority projects for action

==> picture [109 x 10] intentionally omitted <==

==> picture [442 x 396] intentionally omitted <==

CSL BEHRING BROADMEADOWS FUTURE VISION

20 million+ vials in 2030

Our Vision

A world-class facility and network partner, reliably delivering for Our Patients.

Our Mission

We deliver live-saving therapies for Our Patients, collaborating globally to continuously improve production capacity. Our people are committed to delivering excellence, working with agility and innovating to strengthen our business today and deliver for our bright future.

==> picture [103 x 23] intentionally omitted <==

==> picture [122 x 108] intentionally omitted <==

CSL Seqirus A Global Network

Driven by Our Promise to Protect Public Health

Chris Larkins

Jonah Smith

VP Program Lead – Project Banksia

April 2024

SVP, Global Operations

CSL Seqirus growth linked directly to differentiation strategy and core capabilities

==> picture [430 x 307] intentionally omitted <==

----- Start of picture text -----

CSL Seqirus historic growth
Seasonal Influenza Revenue (US$'M)
1,500
23% CAGR
1,000
500
-
FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23
Non-differentiated Differentiated
----- End of picture text -----

==> picture [323 x 317] intentionally omitted <==

----- Start of picture text -----

Cornerstones for Success
Real World Differentiation
Evidence Strategy
Platform
Focus on Scaled
Innovation Manufacturing
Platforms
----- End of picture text -----

==> picture [109 x 10] intentionally omitted <==

==> picture [122 x 77] intentionally omitted <==

CSL Seqirus’s focus within its 4 strategic pillars drives its near and long-term success

1. CONTINUED GROWTH IN INFLUENZA

==> picture [102 x 101] intentionally omitted <==

Opportunities in both new and existing markets to increase our global footprint

3. GROW BEYOND INFLUENZA

==> picture [119 x 98] intentionally omitted <==

Leverage core competence of respiratory vaccines

2. BROADEN OUR PANDEMIC BUSINESS

==> picture [63 x 71] intentionally omitted <==

Multi-pathogen pandemic capability

MANUFACTURING TECHNOLOGY

==> picture [92 x 92] intentionally omitted <==

Common technologies and yield investments to underpin our growth

In influenza, Seqirus will grow the market through differentiation despite lower immunisation rates

==> picture [99 x 91] intentionally omitted <==

Historic Trend (US)

Expectations

==> picture [44 x 8] intentionally omitted <==

----- Start of picture text -----

COVID-19
----- End of picture text -----

==> picture [23 x 18] intentionally omitted <==

----- Start of picture text -----

2009
H1N1
----- End of picture text -----

Influenza still has significant unmet need, particularly in paediatric and older adult populations
Immunisation rates will return over time
Annualisation of COVID-19 boosters will reduce vaccine fatigue
CSL Seqirus growth will outpace the market through differentiation and advocacy efforts

Source: www.cdc.gov

==> picture [109 x 10] intentionally omitted <==

CSL Seqirus focused on continuous innovation to reduce the burden of influenza

==> picture [99 x 91] intentionally omitted <==

==> picture [846 x 337] intentionally omitted <==

----- Start of picture text -----

Multiple
Differentiators
Differentiated
aH5N1c
QIVc
Undifferentiated
aQIVc
aTIV
aQIV
TIVe
sa-mRNA
aH5N1
QIVe Development Status: Development Status:
• QIVc: 6-month+ age extension • aQIVc: Phase III
• aQIV: Advanced Real-World Evidence • sa-mRNA flu: Phase I
----- End of picture text -----

==> picture [109 x 10] intentionally omitted <==

Technologies will be complementary Cell will remain basis of rapid pandemic response for Flu

==> picture [265 x 300] intentionally omitted <==

----- Start of picture text -----

CELL-BASED VACCINE
----- End of picture text -----

MF59 ADJUVANT Squalene

==> picture [137 x 66] intentionally omitted <==

SELF-AMPLIFYING mRNA VACCINE

==> picture [212 x 143] intentionally omitted <==

==> picture [109 x 10] intentionally omitted <==

sa-mRNA technology differentiates

==> picture [94 x 91] intentionally omitted <==

==> picture [93 x 91] intentionally omitted <==

CSL Seqirus COVID-19 vaccine candidate

Differentiators of sa-mRNA Technology

Accelerating to market

Superior response to Omicron strain 1 as a booster in adults vs. approved booster (Phase III)

Licensing and collaboration agreement with Arcturus Therapeutics Inc.
• Finalising clinical programs
• Studying emerging variants
Regulatory submissions

2 Lower dose of mRNA

Global Launches Anticipated in 2024 - 2026

Duration of protection up 3 to 12 months

^ Links to online publications: https://www.medrxiv.org/content/10.1101/2023.07.13.23292597v1.full.pdf

==> picture [90 x 52] intentionally omitted <==

==> picture [90 x 51] intentionally omitted <==

==> picture [87 x 51] intentionally omitted <==

==> picture [92 x 51] intentionally omitted <==

==> picture [354 x 29] intentionally omitted <==

----- Start of picture text -----

Japan EU UK US
(via Meiji Seika)
----- End of picture text -----

https://ir.arcturusrx.com/news-releases/news-release-details/study-shows-novel-sa-mrnavaccines-offer-robust-broad-enduring

==> picture [109 x 10] intentionally omitted <==

CSL Seqirus – Global manufacturing presence

==> picture [127 x 84] intentionally omitted <==

Holly Springs NC, US

The world’s largest cellbased influenza vaccine manufacturing facility

First and only site recognized by the U.S. Government with pandemic-ready designation.
Recent expansion works include new formulation suites and expanded fill and finish capacity

==> picture [128 x 85] intentionally omitted <==

Liverpool, UK

The U.K.’s only injectable influenza vaccine manufacturing facility

Includes proprietary adjuvant, MF59® manufacturing and highspeed fill and finish line
Plays an important role in pandemic preparedness and response for the U.K. and other countries in Europe.

==> picture [129 x 85] intentionally omitted <==

Parkville, Australia

Australia’s first influenza vaccine manufacturer

Manufacture of products of national significance, including antivenoms and the Q fever vaccine.
Produces seasonal and pandemic vaccines for Australia and worldwide.
Develops candidate vaccine viruses for the World Health Organisation

==> picture [128 x 85] intentionally omitted <==

sa-mRNA CTM, NC, US

New sa-mRNA clinical trial

material (CTM) manufacturing facility located within Holly

Springs

Flu Vaccine Clinical Trial Material manufacturing will occur in CSL Seqirus’ Vaccine Pilot Plant (VPP) and SmallScale Filling (SSF) facility at Holly Springs
SSF operationally setup for H5N1 and H2N3

==> picture [128 x 86] intentionally omitted <==

Waltham, MA, US

State-of-the-Art Vaccine Research and Development Facility

Pre-clinical manufacturing
The custom-built Biosafety level 3 laboratory (BSL-3)
The site will serve as CSL's central hub for current and future vaccine design.

==> picture [109 x 10] intentionally omitted <==

Looking Forward

CSL Seqirus is well positioned to continue its success in influenza:
Capacity development well advanced to support aQIVc launch
Continuous innovation will enable CSL Seqirus to outpace market growth:
aQIVc setting new standard of care
sa-mRNA
sa-mRNA technology will differentiate CSL Seqirus vaccine in COVID-19

==> picture [323 x 301] intentionally omitted <==

==> picture [109 x 10] intentionally omitted <==

CSL SEQIRUS TULLAMARINE

==> picture [109 x 10] intentionally omitted <==

CSL Seqirus Tullamarine New World Class Flu Cell Culture facility in Australia to meet growing demand and pandemic protection

==> picture [257 x 149] intentionally omitted <==

==> picture [237 x 149] intentionally omitted <==

==> picture [501 x 163] intentionally omitted <==

==> picture [83 x 319] intentionally omitted <==

Project is on target for schedule and budget, with first production in Q1 2026 Cell culture manufacturing Anti-venom production Best-in-class sustainability paired with innovative production capabilities

==> picture [109 x 10] intentionally omitted <==

Project Objectives

Australian Biosecurity contract:

10-year Biosecurity contract secured with Australian government, commencing in mid-2026
Secure onshore manufacturing capability for cell-based pandemic influenza response and secure supply of Products of National Significance (PNS).

Seasonal influenza vaccine supply:

CSL Seqirus Long Range Plan indicates strong seasonal cell-based influenza demand into the future. Tullamarine FCC (Flu Cell Culture) facility (1 line) provides additional global FCC capacity to support that demand.

Pandemic Supply:

Tullamarine FCC facility provides pandemic capacity to meet future growth in global sales of Pandemic Advance Purchase Agreements (outside of USA).

Critical FCC Milestones:

==> picture [245 x 150] intentionally omitted <==

3 x 5,000 L FCC bioreactors

Key Deliverables:

Increase seasonal cell-based influenza capacity by 50% by NH 26/27 Season
Increase pandemic cell-based influenza capacity by 50% by June 2026
Secure site licensure and product registrations for Biosecurity contract by June 2026
Commence production by Jan 2026, registration in Europe by March 2026

==> picture [109 x 10] intentionally omitted <==

Project Scope

New CSL Seqirus Tullamarine Site

Consolidated Drug Substance & Formulated Bulk Manufacture
```
 - Flu Cell Culture (FCC)
```
Products of National Significance (PNS)
- Supporting QC Laboratories
Supporting Utilities & Warehousing
```
    - Site Administration
```

==> picture [80 x 87] intentionally omitted <==

FUTURE CSL SEQIRUS AUSTRALIAN OPERATIONS

==> picture [80 x 88] intentionally omitted <==

CSL Behring Broadmeadows Site

Pre-filled Syringe and Vial Fill/Finish
Raw Materials, Chemistry & Microbiology Quality Control Testing
Interim Warehousing to support Fill/Finish

Plus 3rd Party Logistics

Finished Product Warehousing

Plus 3rd Party Logistics

Raw Material Warehousing

==> picture [209 x 15] intentionally omitted <==

----- Start of picture text -----

CSL Seqirus Woodend Site
----- End of picture text -----

Venom & Plasma
Production and QC Animal Testing

==> picture [78 x 84] intentionally omitted <==

A NETWORK OF SITES TO DELIVER

==> picture [80 x 89] intentionally omitted <==

New CSL Melbourne Site (Elizabeth Street, Melbourne)

Virus Development (TD Laboratories)

Project Roadmap

Project Delivery (Engineering)

Validation, Licensure & Registration

Design
Construction
Automation
Commissioning and Qualification
Process Qualification, Engineering & Media Simulations
• Process Performance Qualification (PPQ)
Site Licensure & Product Registration

==> picture [925 x 206] intentionally omitted <==

----- Start of picture text -----

Process C&Q
FCC Post-
Tech Transfer FCC
Engineering Runs Process Commercial
and Media Sims Improvement Manufacture
Qualification NH 26/27
window
PPQ
2022 2023 2024 2025 2026
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
----- End of picture text -----

Construction Progress

==> picture [199 x 358] intentionally omitted <==

==> picture [502 x 261] intentionally omitted <==

----- Start of picture text -----

Admin & Labs
PNS
Warehouse
FCC
Utility Yard
----- End of picture text -----

==> picture [109 x 10] intentionally omitted <==

Tullamarine Construction Progress

==> picture [846 x 237] intentionally omitted <==

Project achieving milestones
Certificate of Occupancy received for Admin building
Mechanical & electrical installation complete
Full site hand-over to CSL Seqirus on track for April 2024
FCC and PNS clean rooms practically complete
On track for process validation in Q4 2024
Utilities and Process commissioning underway.

==> picture [109 x 10] intentionally omitted <==

Digital Manufacturing

==> picture [516 x 333] intentionally omitted <==

==> picture [234 x 224] intentionally omitted <==

----- Start of picture text -----

Digital Training
Advanced Analytics
Live Viable Cell Density
----- End of picture text -----

==> picture [171 x 97] intentionally omitted <==

==> picture [109 x 10] intentionally omitted <==

Sustainability Certification

==> picture [248 x 339] intentionally omitted <==

----- Start of picture text -----

Rooftop Solar
----- End of picture text -----

On site renewable energy generation
Electrification of plant to reduce reliance on fossil fuels
Heat recovery from heat decontaminated liquid waste
Water recovery and reuse
Ventilation setback operating modes
Detailed Waste Management / Circular Economy plans to minimise Construction and Operations Waste
Reuse of recycled materials in construction

CSL Seqirus Tullamarine on track for:

✓ 5 star Green Star rating - all buildings
✓ WELL Gold rating - Admin Labs building

==> picture [109 x 10] intentionally omitted <==

QUESTIONS & ANSWERS

==> picture [109 x 10] intentionally omitted <==

AI assistant

CSL Ltd. — Investor Presentation 2024

17854_rns_2024-04-10_98ffa42e-8ee7-4ece-a562-72e9baada009.pdf

CSL Australia Investor Site Tour Presentations

Fiona Mead

For further information, please contact:

IMPORTANT NOTICE AND DISCLAIMER

TRADEMARKS

Acknowledgement of Country

CSL Behring Broadmeadows Investor Tour

Mike Deem

Andrew Hodder

Visitor Safety Procedures

Site Safety Rules

Who we are

Leading global biotech company

CSL group operating structure

Global Biotherapeutics Leader

Global Influenza Vaccines Leader

Global Specialty Pharma Leader

CSL Behring: Driving sustainable, profitable growth

CSL Behring – Global manufacturing presence

Bern, Switzerland

Broadmeadows, Australia

Marburg, Germany

Kankakee, Illinois, US

Wuhan, China

CapEx investments are providing capacity for growth

From donor to patient: Manufacturing plasma biotherapies

WELCOME TO BROADMEADOWS

CSL BEHRING BROADMEADOWS

OUR WORKFORCE

Our Customers

GLOBAL COMMERCIAL SUPPLY

REGIONAL DOMESTIC SUPPLY

CSL BEHRING BROADMEADOWS

Product Portfolio

CSL Behring Broadmeadows

Critical Care

Inhibitors

Wound Healing

Pulmonology

Immunology

Coagulation

CSL Seqirus

MORE THAN A DECADE OF SUSTAINED GROWTH AND ALMOST A$2B IN CAPITAL INVESTMENT

Sustainability Initiatives at Broadmeadows

Local sustainability initiatives

Our Vision

Our Mission

CSL Seqirus A Global Network

Chris Larkins

Jonah Smith

CSL Seqirus growth linked directly to differentiation strategy and core capabilities

1. CONTINUED GROWTH IN INFLUENZA

2. BROADEN OUR PANDEMIC BUSINESS

In influenza, Seqirus will grow the market through differentiation despite lower immunisation rates

Historic Trend (US)

Expectations

CSL Seqirus focused on continuous innovation to reduce the burden of influenza

sa-mRNA technology differentiates

Differentiators of sa-mRNA Technology

Accelerating to market

CSL Seqirus – Global manufacturing presence

Holly Springs NC, US

Liverpool, UK

Parkville, Australia

sa-mRNA CTM, NC, US

Springs

Waltham, MA, US

State-of-the-Art Vaccine Research and Development Facility

Looking Forward

CSL SEQIRUS TULLAMARINE

Project Objectives

Australian Biosecurity contract:

Seasonal influenza vaccine supply:

Pandemic Supply:

Critical FCC Milestones:

3 x 5,000 L FCC bioreactors

Project Scope

CSL Ltd. Investor Presentation 2024